BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 18078628)

  • 1. Severe systemic inflammatory response syndrome in a patient with adult onset Still's disease treated with the anti-IL1 drug anakinra: a case report.
    Guignard S; Dien G; Dougados M
    Clin Exp Rheumatol; 2007; 25(5):758-9. PubMed ID: 18078628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Severe hepatitis in a patient with adult-onset Still's disease treated with anakinra].
    Diallo A; Mekinian A; Boukari L; Mouas H; Zamy M; Nahon P; Gérin M; Fain O
    Rev Med Interne; 2013 Mar; 34(3):168-70. PubMed ID: 23182291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of anakinra in a case of refractory Still disease.
    Debiais S; Maillot F; Luca L; Buret J; Fautrel B; Renard JP
    J Clin Rheumatol; 2008 Dec; 14(6):357-8. PubMed ID: 19033875
    [No Abstract]   [Full Text] [Related]  

  • 4. IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still's disease.
    Naumann L; Feist E; Natusch A; Langen S; Krause A; Buttgereit F; Burmester GR
    Ann Rheum Dis; 2010 Feb; 69(2):466-7. PubMed ID: 20107032
    [No Abstract]   [Full Text] [Related]  

  • 5. Long-term efficacy and safety of Anakinra in a patient with liver transplant due to Adult onset Still's Disease.
    Yilmaz S; Cinar M; Simsek I; Erdem H; Pay S
    Mod Rheumatol; 2014 Nov; 24(6):1030-1. PubMed ID: 24313885
    [No Abstract]   [Full Text] [Related]  

  • 6. Anakinra in children and adults with Still's disease.
    Vastert SJ; Jamilloux Y; Quartier P; Ohlman S; Osterling Koskinen L; Kullenberg T; Franck-Larsson K; Fautrel B; de Benedetti F
    Rheumatology (Oxford); 2019 Nov; 58(Suppl 6):vi9-vi22. PubMed ID: 31769856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adult-onset Still's disease with prominent polyserositis.
    Farooq Sheikh AS; Marks J; Hopkinson N
    Scott Med J; 2018 May; 63(2):63-66. PubMed ID: 29506437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subacute liver failure following anakinra treatment for adult-onset Still disease.
    Aly L; Iking-Konert C; Quaas A; Benten D
    J Rheumatol; 2013 Oct; 40(10):1775-7. PubMed ID: 24085761
    [No Abstract]   [Full Text] [Related]  

  • 9. Cardiac death in a patient with adult-onset Still's disease treated with the interleukin 1 receptor inhibitor anakinra.
    Ruiz PJ; Masliah E; Doherty TA; Quach A; Firestein GS
    Ann Rheum Dis; 2007 Mar; 66(3):422-3. PubMed ID: 17179171
    [No Abstract]   [Full Text] [Related]  

  • 10. Marked effect and steroid-sparing ability of anakinra on a patient with refractory adult-onset Still's disease.
    Tamaki H; Shimizu H; Hiraoka E; Uechi E; Kishimoto M; Yamaguchi K; Okada M
    Mod Rheumatol; 2010 Apr; 20(2):200-4. PubMed ID: 20037747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Anakinra in refractory adult onset Still's disease].
    Vercoutere W; Starmans-Kool M; Peeters RM
    Ned Tijdschr Geneeskd; 2011; 155(18):A2966. PubMed ID: 21466723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuation of anakinra despite the development of a pruritic rash in an otherwise refractory case of adult-onset Still's disease.
    Vordenbäumen S; Ostendorf B; Sander O; Richter J; Schneider M
    Ann Rheum Dis; 2009 Mar; 68(3):450-1. PubMed ID: 19213754
    [No Abstract]   [Full Text] [Related]  

  • 13. The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis.
    Kalliolias GD; Liossis SN
    Expert Opin Investig Drugs; 2008 Mar; 17(3):349-59. PubMed ID: 18321234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective treatment of steroid refractory adult-onset Still's disease with anakinra.
    Maier J; Birkenfeld G; Pfirstinger J; Schölmerich J; Fleck M; Brühl H
    J Rheumatol; 2008 May; 35(5):939-41. PubMed ID: 18464320
    [No Abstract]   [Full Text] [Related]  

  • 15. Successful outcome of two pregnancies in patients with adult-onset Still's disease treated with IL-1 receptor antagonist (anakinra).
    Fischer-Betz R; Specker C; Schneider M
    Clin Exp Rheumatol; 2011; 29(6):1021-3. PubMed ID: 22153586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical, biological and sonographic response to IL-1 blockade in adult-onset Still's disease.
    Priori R; Ceccarelli F; Barone F; Iagnocco A; Valesini G
    Clin Exp Rheumatol; 2008; 26(5):933-7. PubMed ID: 19032833
    [No Abstract]   [Full Text] [Related]  

  • 17. Rapid responses to anakinra in patients with refractory adult-onset Still's disease.
    Fitzgerald AA; Leclercq SA; Yan A; Homik JE; Dinarello CA
    Arthritis Rheum; 2005 Jun; 52(6):1794-803. PubMed ID: 15934079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adult-onset Still's disease in a patient with cystic fibrosis and its successful treatment with anakinra.
    Albersmeyer MP; Hilge RG; Schulze-Koops H; Sitter T
    Rheumatology (Oxford); 2012 Sep; 51(9):1730-2. PubMed ID: 22513144
    [No Abstract]   [Full Text] [Related]  

  • 19. Anakinra treatment in patients with adult-onset Still's disease is fast, effective, safe and steroid sparing: experience from an uncontrolled trial.
    Kalliolias GD; Georgiou PE; Antonopoulos IA; Andonopoulos AP; Liossis SN
    Ann Rheum Dis; 2007 Jun; 66(6):842-3. PubMed ID: 17513574
    [No Abstract]   [Full Text] [Related]  

  • 20. Adult-onset Still's disease with myocarditis successfully treated with the interleukin-1 receptor antagonist anakinra.
    Raffeiner B; Botsios C; Dinarello C; Ometto F; Punzi L; Ramonda R
    Joint Bone Spine; 2011 Jan; 78(1):100-1. PubMed ID: 21036649
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.